NDAORALTABLETPriority Review
Approved
Apr 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Mechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
A Study to Learn More About Tukysa Once it is Out in the Korean Market
Started Jan 2027
600 enrolled
HER2-positive Locally Advanced UnresectableMetastatic Breast Cancer
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Started Apr 2026
650 enrolled
HER2-positive Breast Cancer
Patient Navigation for HER2+ Metastatic Breast Cancer Patients Treated With Tucatinib
Started Apr 2026
26 enrolled
HER2+ Metastatic Breast Cancer (MBC)
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Started Jan 2026
20 enrolled
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
Started May 2025
86 enrolled
Metastatic HER2+ Advanced Breast Cancer
Loss of Exclusivity
LOE Date
Apr 27, 2038
147 months away
Patent Expiry
Apr 27, 2038
Exclusivity Expiry
Jan 19, 2030